Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma
NCT05296070Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Jun 2022
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in marginal zone lymphoma (MZL), sponsored by University of Miami. Started Jun 2022; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05296070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296070.